Jushi Holdings Inc.
JUSHFAbout the company
Jushi Holdings Inc. engages in the retail, distribution, cultivation, and processing of cannabis for medical and adult-use markets in the United States. The company offers flower, vapes, concentrates, infused chews and chocolates, tinctures, capsules, softgels, topicals and RSO, pre-rolls, and infused chocolate bites under the Hijinks, The Bank, The Lab, Tasteology, Uncommon Kind, Nira + Medicinals, Sèche, Shayo, and Carm's Delight Bites brands. It also engages in the sale of bulk raw materials to duly licensed third parties for use in its own finished products.
Investment snapshot
Positive
1
BUY / PASS
Neutral / negative
2 / 13
NEUTRAL / FAIL
Median fair value
$0.09
-78.2% vs price
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 16 investors flag at least one profitability criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #1703 (Top 55%) | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | PASS | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||
| Margin of Safety | N/A | N/A | N/A | -142.3% | N/A | N/A | -357.7% | N/A | N/A | N/A | -488.5% | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-10-28 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-10-28 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30 Latest source filing: 2026-10-28 Score computed: 2026-11-14 | TTM ended 2026-09-30 Latest source filing: 2026-10-28 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-09-01 Latest source filing: 2026-10-28 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 Latest source filing: 2026-10-28 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-31 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 Latest source filing: 2026-10-28 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment Latest source filing: 2026-10-28 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-09-01 Latest source filing: 2026-10-28 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-09-01 · Balance sheet at 2026-09-30 Latest source filing: 2026-10-28 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-31 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-09-01 · Annual history · FY 2025 Latest source filing: 2026-10-28 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-10-28 Score computed: 2026-11-14 | Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-10-28 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-09-01 Latest source filing: 2026-10-28 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Profitability0% pass✓ 3✗ 32▾
No clean pass — all 16 investors flag at least one profitability criterion
Positive EPS (10 years)0/7 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)1/7 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-3036.3%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)1.8% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-53.7M✗BuffettPositive and growingEarnings Variance (10-yr CoV)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROEN/A (negative equity)✗Lynch> 15%EBIT / Enterprise Value2.3%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=2.3%, ROC=5.5%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-16.24%✗PiotroskiROA > 0ROA Change YoY-11.08% -> -16.24% (delta: -5.16%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=4.20%, ROA=-16.24%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY45.9% -> 43.4%✗PiotroskiImproved YoYPre-Tax Income / Revenue✗Dreman>= 8%Net Income / Shareholders' Equity✗Dreman> 12%Margin of Safety✗PabraiP/B < 1.5 or P/E < 15Return on Equity-3036.3% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency1/6 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue2.4%✗Ackman>= 15%Net Income / Shareholders Equity✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-1.0% (2023) -> 1.8% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 43.1% -> 43.4%, operating margin -1.0% -> 1.8%✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-67.17%; #5200/6340 (top 82.0%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+28.79%; #1503/3702 (top 40.6%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.1330; #3822/5884 (top 65.0%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/6 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Debt & Leverage0% pass✗ 15▾
All 12 investors flag JUSHF's debt & leverage
LT Debt vs Net Current AssetsLT Debt $194.5M vs NCA $-19.5M✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: N/A (negative equity), IC: 0.2x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / EquityN/A (negative equity)✗Lynch< 0.33Cash - Long-term Debt$-165.7M✗LynchPositive preferredLT Debt / Total Assets Change41.66% -> 47.16%✗PiotroskiDecreased YoYCurrent Assets / Current Liabilities0.79✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt LevelsN/A (non-positive equity)✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=0.2x, D/EBITDA=5.9x✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)✗AsnessTop 30% of eligible cross-section - Growth0% pass✓ 2✗ 11▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: -4.5% vs Rev: 6.2%✓LynchInventory growth < Revenue growthEPS Growth Direction✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency1/6 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth-4.4%✗Ackman>= 5%Positive EPS Growth Frequency✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 43.1% -> 43.4%, operating margin -1.0% -> 1.8%✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR26.6%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Efficiency0% pass✓ 1✗ 10▾
No clean pass — all 8 investors flag at least one efficiency criterion
Current Ratio0.79✗Graham>= 2.0ROIC (3-5 yr avg)-16.8%✗Buffett> 10%ROIC - WACC-26.8%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)5.5%✗Greenblatt> 25%Current Ratio Change YoY1.05 -> 1.03✗PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.58x -> 0.62x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities0.79✗Dreman> 1.5Return on Invested Capital7.1%✗Munger> 15%ROIC (high and growing)FY2023: ROIC=-1.1%; FY2024: ROIC=6.3%; FY2025: ROIC=4.2%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROICN/A (non-positive net income)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/5 years above 12% (latest 4.2%)✗SleepROIC > 12% in a majority of years - Valuation models0% pass✗ 3▾
JUSHF overvalued: all 3 models price fair value below $0.41 (median $0.09)
Greenblatt fair value$0.17✗Greenblatt-142.3% margin vs $0.41Munger fair value$0.09✗Munger-357.7% margin vs $0.41Ackman fair value$0.07✗Ackman-488.5% margin vs $0.41 - Verdicts7% pass✓ 1✗ 14▾
Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS
Overall verdict✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (2/7)✗GreenblattRank #1703✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (1/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (3/9)✗TempletonFAIL (2/8)✓SleepPASS (3/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (2/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked) - Valuation8% pass✓ 2✗ 26▾
12 of 13 flag JUSHF's valuation — Graham, Lynch, Greenblatt +9 more
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value2.3%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=2.3%, ROC=5.5%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)4.3x✓Dreman< 8xPrice / Book Value per ShareN/A (negative BVPS)✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-66.8%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=2.0%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical Average✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per Share13.5x✓Ackman<= 25Price vs. Trailing Low✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-67.17%; #5200/6340 (top 82.0%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization-1.8726; #6118/6449 (top 94.9%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per ShareN/A (non-positive TBVPS)✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+3.3618; #740/5247 (top 14.1%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization+7.39%; #1103/4519 (top 24.4%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date✗OshaughnessyTop 10% of eligible cross-section - Cash Flow50% pass✓ 7✗ 5▾
5 of 10 pass — Buffett, Pabrai, Marks +2 more object
Free Cash Flow Proxy$-53.7M✗BuffettPositive and growingFCF Positive and Growing$6.1M✓LynchPositive and growingOperating Cash Flow$17.7M✓PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=4.20%, ROA=-16.24%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)4.3x✓Dreman< 8xP/E or FCF YieldFCF Yield=2.0%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive2/6 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap7.6%✓Ackman>= 4%Price / FCF per Share13.5x✓Ackman<= 25Positive Operating Cash Flow frequency2/6 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$6.1M✓Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization+7.39%; #1103/4519 (top 24.4%)✗OshaughnessyTop 10% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 0.0% of shares last year, 0.2% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: revenue, net income, operating income, gross profit, ebit, interest expense, operating cash flow, depreciation amortization, capex. | Q3 FY 2026 2026-07-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $82.3Mcurrent | -- | -- | -- | $108.3Mest. | $64.4Mest. | $141.6Mest. | $123.4Mest. | $766.1Mest. |
| Revenue | $276.5M↑6% | $70.5M↑7% | $71.3M↑10% | $66.4M↑4% | $262.9M↑2% | $257.5M↓4% | $269.4M↓5% | $284.3M↑36% | $209.3M |
| Operating Income | $6.6M↑196% | $3.5M↑50% | $714.0K↓80% | $1.6M↑185% | $4.9M↓55% | $10.9M↑485% | -$2.8M↑99% | -$220.3M↓516% | -$35.8M |
| Net Income | -$55.3M↑16% | -$12.5M↑47% | -$7.3M↑41% | -$19.8M↓17% | -$68.6M↓41% | -$48.8M↑25% | -$65.1M↑68% | -$202.3M↓1099% | $20.3M |
| EPS (Diluted) | -- | $-0.06↑50% | $-0.04↑33% | $-0.10↓11% | $-0.35↓40% | $-0.25↑24% | $-0.33↑77% | $-1.44↓243% | $-0.42 |
| Gross Margin | 44.2%↑4% | 45.9%↓2% | 44.2%↓1% | 45.0%↑11% | 43.4%↓6% | 45.9%↑6% | 43.1%↑28% | 33.6%↓16% | 39.8% |
| Operating Margin | 2.4%↑178% | 5.0%↑40% | 1.0%↓82% | 2.4%↑181% | 1.8%↓56% | 4.2%↑503% | -1.0%↑99% | -77.5%↓354% | -17.1% |
| ROE | 35.9%↓44% | — | — | — | 59.5%↓39% | 97.1%↓91% | 1044.6%↑344% | -427.9%↓3954% | 11.1% |
| Total Debt | $226.8M↑11% | $226.8M↑11% | $230.0M↑15% | $231.4M↑17% | $205.8M↑11% | $186.2M↓12% | $212.6M↑12% | $189.3M↑50% | $126.0M |
| Shareholders' Equity | -$154.0M↓52% | -$154.0M↓52% | -$141.8M↓81% | -$134.8M↓104% | -$115.3M↓130% | -$50.2M↓706% | -$6.2M↓113% | $47.3M↓74% | $182.4M |
| Current Ratio | 0.79↑26% | 0.79↑26% | 0.83↓19% | 1.13 | 1.03↓1% | 1.05↑108% | 0.50↓23% | 0.65↓65% | 1.84 |
| Debt / Equity | -1.47↑27% | -1.47↑27% | -1.62↑37% | -1.72↑42% | -1.78↑52% | -3.71↑89% | -34.11↓952% | 4.00↑480% | 0.69 |
| Operating Cash Flow | $19.0M↑1% | $3.5M↓42% | $793.0K↑141% | $8.6M↑14% | $17.7M↓18% | $21.6M↑750% | -$3.3M↑85% | -$21.4M↓50% | -$14.3M |
| Free Cash Flow | $6.1M↑66% | $637.0K↓48% | -$3.1M↑49% | $5.6M↑59% | $1.6M↓90% | $16.9M↑220% | -$14.1M↑82% | -$78.3M↑13% | -$89.6M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Pharmaceutical Products
JUSHF vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co., Inc.MRK | $364.3B | $147.76 | $65.0B | $18.3B | 34.7% | 0.94 | — | 1.54 | 2/9 | 5/9 | 4/7 | 0/3 | F-Score 4 | 1/11 |
| ABBOTT LABORATORIESABT | $188.0B | $108.52 | $44.3B | $6.5B | 12.5% | 0.25 | 18.2% | 1.58 | 3/9 | 4/9 | 2/7 | 1/3 | F-Score 5 | 3/11 |
| BRISTOL MYERS SQUIBB COBMY | $129.7B | $63.43 | $48.2B | $7.1B | 38.2% | 2.44 | 19.4% | 1.26 | 2/9 | 1/9 | 3/7 | 1/3 | F-Score 8 | 5/11 |
| BIO-TECHNE CorpTECH | $11.4B | $72.80 | $1.2B | $73.4M | 3.8% | — | 8.4% | 3.46 | 4/9 | 3/9 | 3/7 | 0/3 | F-Score 5 | 4/11 |
| REPLIGEN CORPRGEN | $10.7B | $167.79 | $738.3M | $48.9M | 2.3% | 0.26 | 7.5% | 8.37 | 3/9 | 2/9 | 3/7 | 0/3 | F-Score 7 | 5/11 |
| IONIS PHARMACEUTICALS INCIONS | $4.8B | $29.06 | $943.7M | $381.4M | -78.0% | 3.60 | -40.4% | 3.83 | 3/9 | 1/9 | 1/7 | 0/3 | F-Score 4 | 3/11 |
| NEOGEN CORPNEOG | $2.5B | $11.23 | $870.4M | $7.9M | -0.4% | 0.76 | -2.5% | 3.82 | 3/9 | 1/9 | 2/7 | 0/3 | F-Score 6 | 4/11 |
| Pharvaris N.V.PHVS | $2.4B | $33.36 | — | $206.4M | -64.8% | 0.00 | — | — | 0/9 | 0/9 | 2/7 | 0/3 | F-Score 2 | 2/11 |